Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families

Zhi L Teo1, Daniel J Park1, Elena Provenzano2, Catherine A Chatfield1, Fabrice A Odefrey1, Tu Nguyen-Dumont1, kConFab3, James G Dowty4, John L Hopper4, Ingrid Winship5, David E Goldgar6 and Melissa C Southey1*

Abstract

Introduction: Population-based studies of breast cancer have estimated that some PALB2 mutations confer a breast cancer risk (penetrance) comparable to the average pathogenic mutation in BRCA2. As this risk is of clinical relevance, we sought to identify mono-allelic PALB2 mutations and determine their frequencies in multiple-case breast cancer families attending Familial Cancer Clinics in Australia and New Zealand.

Methods: The youngest affected woman, not known to carry a mutation in BRCA1 or BRCA2, from 747 multiple-case breast cancer families participating in kConFab were selected for PALB2 mutation screening. The coding and flanking intronic regions of PALB2 in DNA extracted from blood were screened using high-resolution melt curve analysis with Sanger sequencing confirmation. Where possible, relatives of women found to carry PALB2 mutations were genotyped for the family-specific mutation, mutant transcripts were characterised and breast tumours arising in mutation carriers were recalled and reviewed. Missense mutations were assessed for potential to disrupt protein function via SIFT, Align GVGD and Polyphen-2.

Results: The mutation screen identified two nonsense mutations (PALB2 c.3113G>A in eight women and PALB2 c.196C>T in one woman), two frameshift mutations (PALB2 c.1947_1948insA and PALB2 c.2982_2983insT each in one woman), 10 missense variants, eight synonymous variants and four variants in intronic regions. Of the four PALB2 mutations identified that were predicted to produce truncated protein products, only PALB2 c.1947_1948insA had not previously been reported. PALB2 c.3113G>A and PALB2 c.196C>T were previously identified in the Australian population whereas PALB2 c.2982_2983insT was previously reported in the UK population. Transcripts derived from three of these mutant PALB2 alleles were vulnerable to nonsense-mediated decay. One missense mutation (PALB2 c.2993G>A) was predicted to disrupt protein function via the three in silico assessment methods applied. The majority of breast cancers arising in carriers that were available for review were high-grade invasive ductal carcinomas. Conclusions: About 1.5% (95% CI 0.6 to 2.4) of Australasian multiple-case breast cancer families attending clinics are segregating protein-truncating mutations in PALB2, most being PALB2 c.3113G>A, p.Trp1038*. Given the prevalence, breast cancer risk, and tumour grade associated with this mutation, consideration of clinical PALB2 testing is warranted.

Introduction

Genetic testing for mutations in breast cancer susceptibility genes offers some women and their families the opportunity for risk-reducing intervention, medical risk reduction and gene-targeted therapeutics [1,2]. Testing in Australia and New Zealand is usually limited to BRCA1 (MIM#113705), BRCA2 (MIM#600185) mutations and possibly those of STK11 (MIM#602216), PTEN (MIM#601728) and TP53 (MIM#191170) if relevant clinical syndromic indications are observed. However, due to the rarity of these mutations in known breast cancer susceptibility genes and the fact that they account for less than 30% of the familial breast cancer risk [3], the majority of individuals at high risk of breast cancer do not carry these mutations and the families are clinically managed solely on the assessment of their cancer family history [4].

The search for additional breast cancer susceptibility genes has been of great interest and has successfully led...
to the identification and characterisation of ATM (MIM#607585) [5], BRIP1 (MIM#605882) [6], CHEK2 (MIM#604373) [7], and PALB2 (MIM#610355) [8]. Mutations in these genes are rare and early reports suggested that, on average, they are associated with moderate risks of breast cancer (lower than the high breast cancer risks associated with BRCA1 and BRCA2 mutations) [5,6,8,9]. However, large population-based studies of breast cancer have demonstrated that at least some mutations in these genes are associated with breast cancer risks that are comparable to the average risk associated with BRCA2 mutations [5,9-13].

PALB2, partner and localiser of BRCA2, is a BRCA1- and BRCA2-interacting protein critical for the homologous recombination-based repair of DNA double-strand breaks and checkpoint control functions [14-16]. Bi-allelic mutations in PALB2 explain an unrecognised Fanconi anemia complementation group, designated subtype N (FANCN), and have been found to convey high risk of childhood cancer [17,18]. Heterozygous germline loss-of-function mutations in PALB2 are associated with increased risk of breast cancer. The first PALB2 association study, which involved familial breast cancer cases and unaffected controls from the UK population, reported that the average estimated risk conferred by five PALB2 mutations is 2.3 (95% CI 1.4 to 3.9) [8] but subsequent population-based studies have estimated the risk associated with at least some PALB2 mutations to be much higher [12,13]. For example, PALB2 c.1592delT was identified in 18/1,918 (0.9%) Finnish breast cancer cases, unselected for family history, compared to 6/2,501 (0.2%) in controls (OR 3.94; 95% CI 1.5 to 12.1). Based on families of the 10 affected carriers, PALB2 c.1592delT was estimated to be associated with a 40% (95%CI 17 to 77) risk to age 70 [12]. Similarly, PALB2 c.3113G>A was identified in 5/1,403 (0.4%) unselected breast cancer cases and 0/764 (0%) unaffected controls in the Australian population. The cumulative risk estimated for PALB2 c.3113G>A, using the families of the five carrier cases, was 91% (95% CI 44 to 100) to age 70 [13]. These risks are comparable to the average breast cancer risk associated with carrying a BRCA2 mutation with penetrance to age 70 of 45% (95%CI 31 to 56) [9].

In this study, we screened for germline PALB2 mutations in a sample of 747 women affected with breast cancer (known not to carry a mutation in BRCA1 or BRCA2) from multiple-case breast cancer families participating in the Kathleen Cuningham Foundation Consortium for Research in Familial Breast Cancer (kConFab). This sample represents women and their families who attend Familial Cancer Clinics throughout Australia and New Zealand. We sought to ascertain the prevalence of PALB2 mutations in these women due to the high estimated breast cancer risk associated with at least some PALB2 mutations and to further consider if clinical testing for these mutations is warranted.

Materials and methods

Participants

Women and their families participating in the kConFab resource [19] were selected for this study. The youngest affected female members (designated the proband) of a multiple-case breast cancer family who had provided blood samples (for DNA preparation) and who were known not to carry a mutation in BRCA1 or BRCA2 were included. These participants would have undergone a variety of mutation testing strategies in research and diagnostic settings including Sanger sequencing through Myriad Genetics (Salt Lake City, UT, USA) [19,20]. The eligibility criteria for recruitment of families into kConFab was intended to maximise the number of living potentially high-risk individuals, including carriers of high-penetrance alleles, regardless of breast cancer status. The reports of cancer in the families were verified through medical records or by state-based cancer registries. Where possible, a copy of the final pathology report was obtained with the locations of archival and diagnostic tumour specimens for future requests of paraffin blocks and slides. A pathologist (EP) conducted pathology reviews of the available tumour material, which provided the information on tumour pathology presented in this paper. Histological grade was scored based on the Bloom-Richardson grading system modified by Elston and Ellis [21].

Data on estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor-2 (HER2) status of the PALB2 mutation-associated tumours were collected, if available, from diagnostic laboratories and pathology reports. HER2 status was classified in accordance with clinical guidelines [22] and was considered to be positive if immunohistochemical test results were ranked 3+ (higher than normal amount of HER2 protein was present) or if HER2 gene amplification was demonstrated using fluorescence in situ hybridisation. An immunohistochemical test result of 1+ (normal amount of HER2 protein was present) was classified as negative for HER2 expression while an immunohistochemical test result of 2+ (moderate amount of HER2 protein was present) without a confirmatory fluorescence in situ hybridisation test was classified as equivocal.

All participants provided written informed consent for participation in the study. This study was approved by The University of Melbourne Human Research Ethics Committee.

High-resolution melt curve analysis and Sanger sequencing analysis of PALB2 coding variants

High-resolution melt (HRM) and Sanger sequencing were performed as previously described in Southey et al.
The coding sequences and the flanking intronic sequences of PALB2 [Q86YC2.1] were screened for genetic variants by HRM curve analysis and the variants were confirmed via Sanger sequencing. Genotyping of relatives of the probands found to carry PALB2 mutations was carried out via Sanger sequencing.

**In silico analysis**

The in silico analyses of PALB2 variants were performed using Sorting Intolerant From Tolerant (SIFT) (J. Craig Venter Institute, Maryland, CA, USA) [23-25], Align Grantham Variation Grantham Deviation (Align GVGD) (International Agency for Research on Cancer, Lyon, France) [26-29] and Polymorphism Phenotyping version 2 (Polyphen-2) [30,31], which are freely available web-based programs. Protein multiple sequence alignment (PMSA) of PALB2 was made available through a recent publication [32] and was used in SIFT and Align GVGD. SIFT calculates the probability that an amino acid at a position is tolerated conditional on the most frequent amino acid being tolerated by interrogating the amino acids appearing at each position in the alignment. If the normalised probability is less than the cutoff score of 0.05, the substitution is predicted to be deleterious [25].

The outputs of Align GVGD are combined to provide a seven-tiered genetic risk classifier: C0, C15, C25, C35, C45, C55, and C65 where C0 describes the category of variants least likely to be deleterious and C65 describes the category of variants most likely to be deleterious [28,29]. The HumDiv-trained data set of Polyphen-2 [31] was used for this research. The investigated mutation is categorised as probably damaging (probability score more than 0.85), possibly damaging (probability score between 0.16 and 0.85), and one 'non-carrier' LCL was included as an additional control.

**Reverse transcription PCR**

Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCL) were cultured and prepared for RNA extraction as described by Southey et al. (2003) [33]. LCLs were divided into two equal portions for treatment with 100 mg/ml of cycloheximide to stabilise the transcripts for analysis [34] or no treatment. Both portions were then incubated for four hours at 37°C. Total RNA was isolated from the LCLs using the RNAqueous-4PCR kit (Ambion/Life Technologies, Carlsbad, CA, USA). Deoxyribonuclease 1 (Ambion/Life Technologies) was added to all extracted total RNA prior to their use in reverse transcription (RT) to remove any genomic DNA that could have been eluted with the RNA during the extraction process.

Primers for RT–PCR were designed using the default conditions on the Primer3 software (Whitehead Institute and Howard Hughes Medical Institute). The primers were also designed to ensure the 3’ end of both the forward and reverse primers ended with a ‘GC clamp’ (one G or C base). To further guard against the amplification of genomic DNA, all primers except one (due to restrictions in length) were designed to span exon-exon boundaries. A PALB2 gene-specific primer (GSP) was used for cDNA synthesis via RT for all cell lines (Additional file 1). Primers were ordered from Geneworks (Hindmarsh, South Australia, Australia).

cDNA was synthesised via RT according to the specifications of the Thermoscript RT-PCR system kit (Life Technologies) using 800 ng of total RNA and the PALB2 GSP. RT was performed at 55°C for 50 mins followed by addition of RNase H and incubation for 20 mins at 37°C. Two μl of synthesised cDNA product was subsequently amplified using two units of AmpliTaq Gold DNA Polymerase (Life Technologies) in the presence of 1x PCR Buffer II (Life Technologies), 1.5 mM MgCl2 (Life Technologies), 0.2 mM dNTP (Ambion/Life Technologies), 0.2 μM each of forward and reverse primers in a 50 µl reaction volume. PCR was performed using the PCR conditions suggested by the Thermoscript RT-PCR system kit (Life Technologies). PCR annealing temperature was chosen to be 51°C. No RT controls (extracted total RNA added in place of cDNA during RT–PCR) were added to control for contamination from genomic DNA. Platinum Supermix High Fidelity (Life Technologies) was used to limit the extent to which longer PCR products, resulting from the inclusion of intronic sequences, were not under-represented. RT–PCR was carried out in triplicate for each condition for each LCL. Multiple LCLs (derived from different study participants) carrying each of the mutations was included in the assays whenever possible and one ‘non-carrier’ LCL was included as an additional control.

RT–PCR products were separated using agarose gel electrophoresis on 2%, 3% or 4% agarose gels. Bands were excised from the gel and purified using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions prior to Sanger sequencing analysis.

The relative amounts of DNA product amplified in each RT–PCR reaction were measured by comparing the chromatogram peak heights (fluorescence signal intensities; FSI) of the variant nucleotides of the mutant alleles to the corresponding wild-type nucleotides of the wild-type alleles. After Sanger sequencing, Sequencing Analysis Software (Life Technologies) provides FSIs of each nucleotide of the target amplicon. FSIs of the variant and wild-type nucleotides at the heterozygous PALB2 c.196C>T position were recorded. FSIs of three wild-type nucleotides and their corresponding variant nucleotides in regions of frameshift resulting from PALB2 c.1947_1948insA or
PALB2 c.2982_2983insT were recorded for each condition (cycloheximide treated or non-cycloheximide treated). FSIs of six wild-type nucleotides and their corresponding six variant nucleotides in regions of frameshift resulting from PALB2 c.3113G>A were recorded for each treatment condition. The same three or six nucleotides in the regions of frameshift were interrogated for each mutant transcript in the same sequencing direction. A proportion of the FSI of the variant nucleotide to that of the corresponding wild-type nucleotide was obtained. In the situations where three or six nucleotides were interrogated per treatment condition, the FSI proportions of the three or six nucleotides were averaged within a treatment condition. The FSI proportions of the technical replicates of each treatment condition were averaged. The difference in the mean FSI proportions of the technical replicates of each treatment condition were averaged within a treatment condition. The FSI proportions of the three or six nucleotides in regions of frameshift were observed in 11 (1.5%) of the 747 probands. Eight were missense variants, and the remaining eight were synonymous variants. Four variants were identified in the intronic region of PALB2, three of these were single-base changes and one was an insertion of three bases towards the 5’ end of intron 4. 10 of the 26 variants had not been previously reported (Table 1).

The four nonsense and frameshift PALB2 mutations were observed in 11 (1.5%) of the 747 probands. Eight probands (0.9%) were found to carry PALB2 c.3113G>A while PALB2 c.196C>T, PALB2 c.196C>T, PALB2 c.1947_1948insA and PALB2 c.2982_2983insT were each carried by a single proband. PALB2 c.1947_1948insA has not been previously reported in published literature or in the National Centre for Biotechnology Information (NCBI [35]) or the e!Ensembl [36] genome databases. PALB2 c.2982_2983insT had not been previously reported in the Australian or New Zealand population.

In silico analysis
The 10 exonic missense variants were analysed for their predicted effect on protein function using SIFT [23-25], Align GVGD [26,37], and Polyphen-2 [30,31] programs. PALB2 c.2993G>A, p.Gly998Glu was the only PALB2 variant predicted to be deleterious to protein function by all three programs (Table 2).

Transcript analysis
Figure 1 shows the outcome of the RT-PCR assays and the semi-quantitative analysis of nonsense-mediated decay (NMD) observed for the four PALB2 nonsense and insertion mutations identified in this study. The results of each mutation are discussed in the following sections.

PALB2 c.3113G>A
PALB2 c.3113G>A is a nonsense mutation located at the last nucleotide of exon 10. Two alternate transcripts were observed in the RT-PCR assays. One alternate transcript involved the deletion of exon 10 (117bp; PALB2 r.2997_3113del, p.Gly1000_Gly1038del), and the other included a 31bp deletion in exon 10 (PALB2 r.3083_3113del, p.Gly1028fs*3) that resulted in a shift of reading frame and a premature termination codon (PTC) (at codon 1030). These two transcripts were also observed to travel in the agarose gel as heteroduplexes with the wild-type allele (Figure 1a, agarose gel bands A and B). Cycloheximide treatment of LCLs carrying this mutation demonstrated that PALB2 r.2997_3113del does not undergo extensive NMD whereas PALB2 r.3083_3113del appears to be susceptible to NMD (Figure 1a).

PALB2 c.196C>T
PALB2 c.196C>T is a nonsense mutation predicted to produce a truncated protein (p.Gln66*). Figure 1b shows that no alternate transcripts resulted from this mutation and that the cycloheximide treatment of all LCLs (both wild-type and those carrying PALB2 c.196C>T) had considerable impact on transcript stabilization compared to the untreated LCLs as visualised on the agarose gel. Comparison of the FSI of the mutant and wild-type alleles derived from Sanger sequencing of the RT-PCR products (semi-quantitative analysis) suggests that the wild-type transcript might be more sensitive to cycloheximide treatment than the mutant allele. Taken together, the data suggest that PALB2 c.196C>T is not vulnerable to NMD.

PALB2 c.1947_1948insA and PALB2 c.2982_2983insT
Both PALB2 c.1947_1948insA and PALB2 c.2982_2983insT are frameshift mutations predicted to produce a PTC each (p.Glu650fs*13 and p.Ala995fs*16, respectively) and are not located in splice-site consensus sites. The relative levels of expression of the PALB2 c.1947_1948insA and PALB2 c.2982_2983insT mutant alleles in the non-cycloheximide-treated LCLs were 56% less and 63% less,
Table 1 PALB2 variants identified in female participants of the kConFab resource.

| Exonic variants | Nucleotide change | Protein change | rs number | Frequency (n = 747) | % | References |
|-----------------|-------------------|----------------|-----------|---------------------|---|------------|
| Nonsense        | c.196C>T         | p. Gln66*      | rs180177083 | 1                   | 0.1 | Casadei et al. [38]; Wong et al. [39] |
|                 | c.3113G>A        | p. Trp1038*    | rs180177132 | 7                   | 0.9 | Rahman et al. [8]; Casadei et al. [38]; Wong et al. [39] |
| Frameshift      | c.1947_1948insA  | p. Glu650fs*13 | -         | 1                   | 0.1 | - |
|                 | c.2982_2983insT  | p. Ala995fs*16 | rs180177127 | 1                   | 0.1 | Rahman et al. [8]; Bogdanova et al.[70] |
| Missense        | c.90G>T          | p. Lys30Asn    | -         | 1                   | 0.1 | - |
|                 | c.94C>G          | p. Leu32Val    | rs151316635 | 1                   | 0.1 | - |
|                 | c.596A>G         | p. Asp219Gly   | rs45594034  | 1                   | 0.1 | Rahman et al. [8]; Casadei et al. [38]; Wong et al. [39]; Dansonka-Mieskowska et al.[61] |
|                 | c.956C>A         | p. Ser319Tyr   | -         | 1                   | 0.1 | - |
|                 | c.1010T>C        | p. Leu337Ser   | rs45494092  | 25                  | 3.3 | Rahman et al. [8]; Hellebrand et al. [40], Garcia et al. [63], Bogdanova et al. [70] |
|                 | c.1475G>T        | p. Gly492Val   | -         | 1                   | 0.1 | - |
|                 | c.1676A>G        | p. Gln559Arg   | rs152451   | 72                  | 9.6 | Rahman et al. [8]; Hellebrand et al. [40], Garcia et al. [63], Bogdanova et al. [70] |
|                 | c.2014G>C        | p. Glu672Gln   | rs45532440  | 51                  | 6.8 | Rahman et al. [8]; Hellebrand et al. [40], Garcia et al. [63], Bogdanova et al. [70]; Dansonka-Mieskowska et al.[61] |
|                 | c.2590C>T        | p. Pro864Ser   | rs45568339  | 1                   | 0.1 | Rahman et al. [8]; Hellebrand et al. [40], Garcia et al. [63] |
|                 | c.2993G>A        | p. Gly998Glu   | rs45551636  | 17                  | 2.3 | Rahman et al. [8]; Hellebrand et al. [40], Garcia et al. [63], Bogdanova et al. [70] |
| Synonymous      | c.1431C>T        | p. Thr477Thr   | -         | 1                   | 0.1 | - |
|                 | c.1470C>T        | p. Pro490Pro   | rs45612837  | 1                   | 0.1 | Rahman et al. [8]; Bogdanova et al.[70] |
|                 | c.1572A>G        | p. Ser524Ser   | rs45472400  | 4                   | 0.5 | Rahman et al. [8]; Hellebrand et al. [40], Garcia et al. [63], Bogdanova et al.[70] |
|                 | c.1935G>A        | p. Glu645Glu   | rs141707455 | 1                   | 0.1 | Hellebrand et al. [40], Garcia et al. [63], Bogdanova et al.[70] |
|                 | c.2469C>A        | p. Leu823Leu   | -         | 1                   | 0.1 | - |
|                 | c.2823C>A        | p. Ile941Ile   | -         | 1                   | 0.1 | - |
|                 | c.3300T>G        | p. Thr1100Thr  | rs45516100  | 45                  | 6   | Rahman et al. [8]; Hellebrand et al. [40], Garcia et al. [63], Bogdanova et al.[70]; Dansonka-Mieskowska et al.[61] |
|                 | c.3321G>A        | p. Leu1107Leu  | -         | 1                   | 0.1 | - |
| Intronic variants | c.-47G>A       | -               | rs8053188  | 17                  | 2.3 | Hellebrand et al. [40], Garcia et al. [63] |
|                 | c.212-58A>C      | -               | rs80291632  | 37                  | 5   | Garcia et al. [63], Dansonka-Mieskowska et al.[61] |
|                 | c.1684+41_42InsTGA | -           | -         | 2                   | 0.3 | - |
|                 | c.2834+12C>T     | -               | -         | 1                   | 0.1 | - |
respectively, than the corresponding mutant allele in the
cycloheximide-treated LCLs. This suggests that transcripts
arising from both these mutant alleles are subjected to
NMD (Figure 1c and 1d). RT-PCR comparison of the
transcripts respectively, than the corresponding mutant allele in the

diagnoses of breast cancer and was also affected with six
cancers (Table 3a). The families of the eight probands had at least
one was ER+/PR+/HER2+ and one was ER+/PR+/HER2-

tumours of two of these probands were available,
pleomorphic lobular carcinoma(ER+/PR+/HER2+) diag-
Table 2 Predicting the effects of
PALB2 missense variants on protein function using three in silico methods.

| Nucleotide change | Protein change | Carrier frequency (%) | SIFT a | Align GVGD b | Polyphen c |
|-------------------|----------------|-----------------------|--------|--------------|------------|
| c.90G>T           | p.Lys30Asn     | 1 (0.1)               |        |              |            |
| c.94C>G           | p.Leu32Val     | 1 (0.1)               |        |              |            |
| c.596A>G          | p.Asp219Gly    | 1 (0.1)               |        |              |            |
| c.956C>A          | p.Ser319Tyr    | 1 (0.1)               |        |              |            |
| c.1010T>C         | p.Leu337Ser    | 25 (3.3)              |        |              |            |
| c.1475G>T         | p.Gly492Val    | 1 (0.1)               |        |              |            |
| c.1676A>G         | p.Gln559Arg    | 72 (9.6)              |        |              |            |
| c.2014G>C         | p.Glu672Gln    | 51 (6.8)              |        |              |            |
| c.2590C>T         | p.Pro864Ser    | 1 (0.1)               |        |              |            |
| c.2993G>A         | p.Gly998Glu    | 17 (0.9)              |        |              |            |

**Family histories and tumour characteristics**

The relatives of women who were identified as carriers of
PALB2 c.3113G>A, PALB2 c.196C>T, PALB2 c.1947_1948insA, and PALB2 c.2982_2983insT, were genotyped
for the respective family mutations. Several more carriers
were identified (Table 3).

PALB2 c.3113G>A was identified in eight probands. The
dataset at diagnosis (not including second primary
diagnosis of breast cancer) of these probands was 48.5
years (range: 32 to 79 years). Tumour material was not
available for the proband of pedigree A (Table 3a). The
other seven probands were of histological grade two or
three. Five of seven probands were found to have invasive
ductal carcinoma as the primary histological type. One of
seven probands had tubular carcinoma and the remaining
proband had lobular carcinoma. The ER, PR and HER2 sta-
tus of the tumours of two of these probands were available,
one was ER+/PR+/HER2+ and one was ER+/PR+/HER2-
(Table 3a). The families of the eight probands had at least
one additional breast cancer diagnoses. Four families had
six diagnoses of breast cancer. Three families were affected
with several other types of cancers (Table 3a).

The proband that was found to carry PALB2 c.196C>T
had a histological grade three, invasive ductal carcinoma
diagnosed at the age of 43 years. The tumour was found
to be positive for ER and PR expression but the HER2
expression status was unknown. The family had nine
diagnoses of breast cancer and was also affected with six
other types of cancers (Table 3b).

The proband that was identified as a carrier of PALB2
c.1947_1948insA had a histological grade two, pleo-
morphic lobular carcinoma (ER+/PR+/HER2+) diag-

Discussion

High throughput screening of the PALB2 coding
and flanking intronic regions in 747 affected women from
multiple-case breast cancer families identified 26 differ-
ent PALB2 genetic variants.

The four mutations that were predicted to produce
truncated protein product were identified in a total of 11
(1.5%) of the 747 women screened. Eight of these women
were found to carry PALB2 c.3113G>A that has pre-
viously been identified in British, Australian and Ameri-
can women affected with breast cancer [8,13,38,39] and
is associated with an estimated 91% (95% CI 44 to 100)
cumulative risk of breast cancer to age 70. We report this
and the carrier frequency of PALB2 c.3113G>A in the
ekConFab resource in Southey et al., (2010) [13]. PALB2
c.2982_2983insT has previously been identified in one of

where possible, tumour material was also collected for
some family members affected with breast cancer. In
summary, PALB2-associated tumours are mostly high
histological grade invasive ductal carcinoma (11/15; 73%).
A total of 2/15 (13%) were pleomorphic lobular

carcinomas, 1/15 (7%) was a lobular (classical) carcinoma
and 1/15 (7%) was a tubular carcinoma.
Figure 1 Characterisation of PALB2 mutation transcripts via RT-PCR. (a) Image of transcripts from PALB2 c.3113G>A visualised on 3% agarose gel. (A) Heteroduplex of the RT-PCR products of the wild-type and the PALB2 r.2997_3113del transcripts. (B) Heteroduplex of the RT-PCR products of the wild-type and PALB2 r.3083_3113del transcripts. (C) RT-PCR product of the wild-type transcript. (D) RT-PCR product of the PALB2 r.3083_3113del transcript. FSIs of six wild-type and their corresponding six variant nucleotides at heterozygous positions were recorded for each condition (CT and NCT). Averaged proportions of FSI of the six variant nucleotides to the FSI of the six corresponding wild-type nucleotides for each condition are shown. (b) Image of wild-type transcripts and transcripts from PALB2 c.196C>T visualised on 4% agarose gel. FSIs were recorded for the variant and corresponding wild-type nucleotide at the heterozygous position. (c) Image of transcripts resulting from PALB2 c.1947_1948insA visualised on 2% agarose gel. FSIs were recorded for three variant nucleotides and their corresponding wild-type nucleotides at the heterozygous position. (d) Image of transcripts from PALB2 c.2982_2983insT visualised on 2% agarose gel. FSIs were recorded for three variant nucleotides and their corresponding wild-type nucleotides at the heterozygous positions. NCT-CT: the difference in FSI proportions in the CT and NCT conditions indicates the semi-quantitative change in relative gene expression levels of the mutant transcripts in each condition. CT, cycloheximide treated; FSI, fluorescence signal intensity; NCT, non-cycloheximide treated; NT, nucleotide; WT, wild-type.
Table 3 Family cancer histories of probands, carriers of PALB2 mutations, and the histopathology features of PALB2-associated tumours.

| Mutation       | Pedigree | Breast cancer diagnoses | Grade | Histological type (1°) | ER | PR | HER2 |
|----------------|----------|-------------------------|-------|-----------------------|----|----|------|
| **a)** PALB2 c.3113G>A | A        | Proband +               |       |                       |    |    |      |
|                |          | FFCOR +                 |       |                       |    |    |      |
|                |          | P.cousin -              |       |                       |    |    |      |
|                |          | P.aunt                  |       |                       |    |    |      |
|                | B        | Proband +               | 3     | IDC                   | pos| neg| Eqv  |
|                |          | P.aunt                  |       |                       |    |    |      |
|                |          | P.cousin -              |       |                       |    |    |      |
|                |          | P.cousin                |       |                       |    |    |      |
|                |          | P.g.mother              |       |                       |    |    |      |
|                | C        | Proband +               | 1     | Tubular               | pos| pos| neg  |
|                |          | Sister +                | 3     | IDC                   | pos| neg|      |
|                |          | P.aunt                  |       |                       |    |    |      |
|                |          | M.aunt                  |       |                       |    |    |      |
|                |          | M.cousin                |       |                       |    |    |      |
|                | D        | Proband +               | 2     | IDC*                  |     |    |      |
|                |          | Sister +                | 1     | IDC                   |     |    |      |
|                |          | P.cousin +              |       |                       |    |    |      |
|                |          | P.cousin                |       |                       |    |    |      |
|                |          | P.aunt                  |       |                       |    |    |      |
|                | E        | Proband +               | 3     | IDC                   | neg| neg| Eqv  |
|                |          | Sister                  |       |                       |    |    |      |
|                |          | M.cousin +              |       |                       |    |    |      |
|                |          | M.cousin                |       |                       |    |    |      |
|                |          | M.cousin +              | 2     | Pl. lobular           | pos| pos|      |
|                |          | M.aunt                  |       |                       |    |    |      |
|                | F        | Proband +               | 3     | IDC                   | pos| pos| pos  |
|                |          | Sister                  |       |                       |    |    |      |
|                | G        | Proband +               | 2     | Lobular               |     |    |      |
|                | H        | Proband +               | 2     | IDC                   | pos| neg| Eqv  |
|                |          | Sister                  | 2     | IDC                   | pos| pos|      |
|                |          | Mother                  |       |                       |    |    |      |
|                |          | M.g.mother              |       |                       |    |    |      |
| **b)** PALB2 c.196C>T | I        | Proband +               | 3     | IDC                   | pos| pos|      |
|                |          | Mother                  |       |                       |    |    |      |
|                |          | P.cousin                |       |                       |    |    |      |
|                |          | P.cousin                |       |                       |    |    |      |
|                |          | P.g.-g.mother           |       |                       |    |    |      |
|                |          | P.g.aunt                |       |                       |    |    |      |
|                |          | P.g.aunt                |       |                       |    |    |      |
|                |          | P.g.aunt                |       |                       |    |    |      |
|                | c) PALB2 c.1947_1948insA | J    | Proband +               | 2     | Pl. lobular           | pos| pos| pos  |
|                |          | Sister                  |       |                       |    |    |      |
|                |          | M.cousin                |       |                       |    |    |      |
|                |          | M.cousin                |       |                       |    |    |      |
923 women from multiple-case breast cancer families screened for PALB2 mutations in a UK study (and not in 1,084 unaffected women) [8]. PALB2 c.196C>T has previously been reported to be carried by 2/972 (0.2%) and 1/70 (1.4%) familial breast cancer cases (and none in controls) in Australian and USA studies, respectively [38,39]. The PALB2 c.1947_1948insA mutation has not been previously reported.

Only one of 10 missense variants identified in this study was predicted to be deleterious by SIFT, Align GVGD and Polyphen-2. This variant, PALB2 c.2993G>A, has previously been identified in studies examining the role of PALB2 in multiple-case breast cancer families that are not known to carry BRCA1 or BRCA2 mutations. A study involving individuals in the UK population found the minor allele frequency of PALB2 c.2993G>A to be 33/1846 (1.8%) for familial breast cancer cases and 44/2168 (2.0%) for unaffected controls [8]. Similar carrier frequencies of this PALB2 variant in breast cancer cases and unaffected controls were also observed in the Finnish population [40]. The results of these studies provide no evidence to suggest that PALB2 c.2993G>A is associated with breast cancer risk. These finding are consistent with the report of Tischkowitz et al. (2012) in that we find no evidence that rare PALB2 missense mutations strongly influence breast cancer risk [32].

The four mutations that were predicted to produce truncated protein products were assessed for their effects on splicing and gene expression. PALB2 c.3113G>A was observed to lead to altered splicing of transcripts. In this study, we identified two mutant transcripts that disrupt the tenth coding exon of PALB2. Casadei et al. (2011) conducted a similar analysis and detected a third transcript (designated p.Trp1038*) in extremely low abundance (4%) [38]. The reason for the apparent discrepancy between the two studies could lie in the methodological approaches utilized as EBV transformation of LCLs, RT-PCR, gel electrophoresis and Sanger sequencing all have small inherent margins to miss transcripts that are present in low quantities. It is also possible that distinct genetic background inherent to the different LCLs (derived from different people) could contribute to the different sensitivities of transcript detection between the two studies. PALB2 c.196C>T, PALB2 c.1947_1948insA, and PALB2 c.2982_2983insT were not found to alter splicing.

The transcripts that contained PTCs occurring more than 55 nucleotides from the 3’ untranslated region and/or the mRNA molecule were removed by the ribosome after the first round of translation [41-44]. NMD-resistant PTC-containing mRNAs based on the recognition of EJC’s have previously been reported for several genes [45-47]. It has since been postulated that mammalian EJCs evolved to function as NMD enhancers and that the basic EJC-independent mechanism proposed for NMD in Saccharomyces cerevisiae, in which the close proximity of poly(A)-binding proteins inhibit NMD [48,49], is still conserved in higher eukaryotes [50,51]. The basic EJC-independent mechanism has been observed in humans [52]. The proximity of the PTC and the poly(A) tail depends on the number of nucleotides and/or the physical distance between them. The latter depends on the three-dimensional structure of the 3’ untranslated region and/or the mRNA molecule that could be affected by intramolecular base pairing, the interaction of the mRNA with RNA-binding proteins and/or the interactions between the proteins involved in translation events. In the context of this study, the three-dimensional structure of mutant PALB2 transcripts could result in the close proximity of the poly(A) tail and the PTC resulting from PALB2 c.196C>T, therefore, attenuating NMD. The presence of truncated proteins in cells from mutation carriers requires further experimental validation.

Table 3 Family cancer histories of probands, carriers of PALB2 mutations, and the histopathology features of PALB2-associated tumours. (Continued)

|                  | Sister in law | Maunt |
|------------------|--------------|-------|
| K                | Proband + | 3 | IDC | pos | neg | pos |
| Sister +         | 2-3 | IDC | pos | neg | pos |
| d) PALB2 c.2982_2983insT | 3 | IDC | pos | neg | pos |

Histopathology and carrier status information were presented where available. "Secondary histological type is lobular carcinoma. Dx, diagnosis; 1°, primary; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor-2; P, paternal; M, maternal; G, grand; G-G, great-grand; FCOR, first cousin once removed; IDC, invasive ductal carcinoma; Pos, positive; Neg, negative; +, genotyped and identified to be a carrier of the respective PALB2 mutation; -, genotyped and found to not be a carrier of a PALB2 mutation; Pl, pleomorphic; Uk, unknown; Eqv, equivocal, tested to be 2+ by immunohistochemistry but not confirmed by fluorescence in situ hybridisation.
Previous studies localised amino acids 21 to 39 of BRCA2 as the region which interacted with PALB2 amino acids 1022 to 1186 [14,53,54]. The evolutionarily conserved coiled-coil domain at the N-terminus of PALB2 (amino acids 6 to 90; Figure 2) interacts with a region of BRCA1 (amino acid 1393 to 1476), which also contains a conserved coiled-coil domain [15,16]. RAD51 and MORF4L1 are also binding partners of PALB2 [55-57]. Amino acid residues in the regions of 101 to 184 and 850 to 1186 of PALB2 bind to RAD51 and, in the presence of BRCA2, guide it to chromosomal lesions and enhance its performance in initiating DNA repair [56]. MORF4L1 binds to a region included in amino acid residues 611 to 764 of PALB2 [55,57] and has been suggested to mediate DNA damage response functions of the BRCA complex in chromatin [57]. PALB2 c.196C>T, PALB2 c.1947_1948insA, PALB2 c.2982_2983insT and PALB2 c.3113G>A would affect the binding between PALB2 and at least one of its binding partners (if they encode stable prematurely truncated proteins). Subsequent potential consequences include impaired homologous recombination repair of DNA double-strand breaks [14-16,56,57]. Functional assays are required to elucidate the full extent of the disruption caused by PALB2 mutations to the function(s) of PALB2 and on their impact on homologous recombination repair.

The families of several probands identified in this study as carriers of frameshift or nonsense mutations of PALB2 were observed to include numerous diagnoses of other cancers. Leukaemia, lymphoma, melanoma, and cancers of the bowel, colon, endometrium, lung, ovary, pancreas, and prostate were repeatedly observed (three diagnoses or more) in and across families (data not shown). PALB2 mutations have been associated with predisposition to pancreatic [58-60] and ovarian cancers [61,62], which were both observed in families identified in our study. The possible implication of PALB2 as a predisposition gene in other cancers would need to be

---

**Figure 2 PALB2 protein structure, binding sites of protein partners and transcript alterations due to PALB2 mutations** Schematic diagram of the PALB2 protein showing its predicted functional domains, binding sites of its protein partners and the mutant transcripts resulting from PALB2 mutations identified in this study.
further investigated. Given the rarity of PALB2 mutations, studies that involve large numbers of PALB2 mutation carriers would be required and could be facilitated through international efforts to combine data sets.

The tumour pathology of breast cancers arising in women who carry germline nonsense or frameshift mutations in PALB2 was examined. Our study found that the majority of tumours that were available for analysis were high histological grade invasive ductal carcinomas (11/15; 73%), two (13%) were pleomorphic lobular carcinomas, one (7%) was a lobular (classical) carcinoma and one (7%) was a tubular-type carcinoma. Although previous studies had noted that breast cancers arising in PALB2 mutation carriers were more likely to be ER-/-PR-/HER2-(triple negative) [61,63-65], the triple-negative receptor status was not observed in our study. Further work is warranted to examine the pathology of breast cancers arising in PALB2 mutation carriers.

PALB2 mutation detection was conducted with the application of HRM analysis involving all coding and flanking intronic regions of the gene. Methods specific for the detection of large genomic rearrangements were not applied. Prior reports demonstrate that such mutations in PALB2 are extremely rare and thus omission of such an analysis is unlikely to significantly impact on this study [60].

Conclusion
We report the identification of two nonsense and two frameshift mutations of PALB2 in 1.5% of familial breast cancer cases recruited from Familial Cancer Clinics in Australia and New Zealand. Although rare, PALB2 mutations have been shown to confer high risks for the development of breast cancer [12,13,66]. Our data, together with that of many others [8,32,38,67-69] have shown that the prevalence of PALB2 mutations in the context of multiple-case breast cancer families is potentially relevant to their clinical management. Data support the inclusion of PALB2 in multi-gene panels, screened by targeted massively parallel sequencing, which are gradually being introduced as part of genetic testing. This will enable PALB2 mutations carriers to be provided with the best available prevention and clinical management, including screening recommendations.

Additional material

Additional file 1: Primer sequences used for reverse transcription PCR. Tabular data, Excel spreadsheet, .xls.

Abbreviations
Align GVGD, Align Grantham Variation Grantham Deviation; EBV, Epstein-Barr virus; EJC, exon junction complex; ER, estrogen receptor; FANCN, Fanconi anemia complementation group, designated subtype N; FSI, fluorescence signal intensities; GSP, gene-specific primer; HER2, human epidermal growth factor-2; HRM, high-resolution melt; kConFab, Kathleen Cunningham Foundation Consortium for Research in Familial Breast Cancer; LCL, lymphoblastoid cell lines; NCBI, National Centre for Biotechnology Information; NMD, nonsense-mediated decay; PMSA, protein multiple sequence alignment; Polyphen-2, polymorphism phenotyping version 2; PR, progesterone receptor; PTC, premature termination codon; RT, reverse transcription; SIFT, Sorting Intolerant From Tolerant.

Authors’ contributions
ZLT conducted the laboratory-based work, analysed the data, contributed to obtaining grant funding, co-wrote the manuscript and approved the final version. DJP supervised aspects of the bench work, contributed to obtaining grant funding, co-wrote the manuscript and approved the final version. EP conducted pathology review of the histopathology slides, independently graded and typed the PALB2-associated tumours, analysed the data, co-wrote the manuscript and approved the final version. TN-D contributed to data analysis and in obtaining grant funding, co-wrote the manuscript and approved the final version. CAC conducted the tissue culture aspects of this bench work and approved the final version of the manuscript. JGD contributed to obtaining all necessary approvals and clearances to conduct the research, contributed to obtaining grant funding, supervised aspects of the research, contributed to the analysis of the data, co-wrote the manuscript and approved the final version. kConFab provided the research resource utilised in this report. FAC supervised aspects of the bench work, contributed to obtaining grant funding, co-wrote the manuscript and approved the final version. JLI contributed to obtaining all necessary approvals and clearances to conduct the research, contributed to obtaining grant funding, supervised aspects of the research, contributed to the analysis of the data, co-wrote the manuscript and approved the final version. IW contributed to obtaining all necessary approvals and clearances to conduct the research, contributed to obtaining grant funding, supervised aspects of the research, contributed to the analysis of the data, co-wrote the manuscript and approved the final version. kConFab is supported by grants from the National Breast Cancer Foundation and the Cancer Foundation of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia. This work was also supported by the NHMRC (Project Grant APP1029974) and the Victorian Breast Cancer Research Consortium (VBCRC). ZLT was supported by Postgraduate Scholarships provided by the Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne and the NHMRC (Dora Lush Postgraduate Fellowship). TN-D is the recipient of a postdoctoral fellowship from the Susan G. Komen for the Cure Foundation. MCS is a NHMRC Senior Research Fellow and a Group Leader of the VBCRC. JLIH contributed to obtaining grant funding, supervised the research, analysed the data, co-wrote the manuscript and approved the final version.

Competing interests
The authors declare that they have no competing interests.

Acknowledgements
We wish to thank Heather Thorne (OAM), Eveline Niedermayr, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study (funded 2001-2009 by the National Health and Medical Research Council of Australia (NHMRC) and currently by the National Breast Cancer Foundation and Cancer Australia (e638333)) for their contributions to this resource, and the many families who contribute to kConFab. kConFab is supported by grants from the National Breast Cancer Foundation, the NHMRC and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western Australia.
References

1. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Wetzell JN, Fredlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.

2. Ashworth A: A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008, 26:3785-3790.

3. Maivadat N, Antoniou AC, Easton DF, Garcia-Closas M: Genetic susceptibility to breast cancer. Mol Oncol 2010, 4:174-191.

4. National Breast and Ovarian Cancer Centre: Advice about familial aspects of breast cancer and epithelial ovarian cancer: a guide for health professionals. Book Advice about familial aspects of breast cancer and epithelial ovarian cancer: A guide for health professionals National Breast and Ovarian Cancer Centre, 2010.

5. Bernstein JL, Teraoka S, Southey MC, Jenkins MA, Andrulis IL, Knight JA, John EM, Lamire-Peltzer W, Whittemore AS, West D, Seminara D, Olsson ER, Spurdle AB, Chenevix-Trench G, Giles GG, Hopper JL, Connanon P: Population-based estimates of breast cancer risks associated with AT, MG and BRCA2 gene variants. Breast Cancer Res 2006, 8:R42.

6. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Dalman RL, Odefrey FA, Southey MC, Marker S, Rahman N: Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res 2008, 10:R87.

7. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Rahman N, Seal S, Thompson D, Kelly P, Barfoot R, Chagtai T, Teo ZL, Dowty JG, Auerbach AD, Rahman N: PALB2 links Fanconi anemia subtype FA-N and predisposes to childhood cancer. Nat Genet 2007, 39:162-164.

8. Rahman N: Fanconi anemia is a defect in the BRCA2 partner PALB2. Nat Rev Cancer 2009, 9:159-161.

9. Mann GJ, Thorne H, Balevich RL, Butow PN, Clarke CL, Edkins E, Evans GM, Foulkes WD, Hopper JL; kConFab for the Breast Cancer Family Registry: Population-based estimates of breast cancer risks associated with BRCA1 or BRCA2 mutations. Nat Genet 2007, 39:1342-1354.

10. Elston CW, Ellis IO, Pinder SE: Pathological prognostic factors in breast cancer. Crit Rev in Oncol Hematol 1999, 31:209-223.

11. Wolff AC, Hammond ME, Schwartz JN, Allred DC, Cote RJ, Dowsett M, Fritsch S, Goh KL, Hayes DF, Palma S, Poisson SI, Pritchard KI, Senn HJ, Hacker NF, Hayes DF, American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guidelines recommendation for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.

12. Sy SMH, Huen MSY, Chen J: PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 2009, 106:7155-7160.

13. Zhang F, Ma J, Wu JX, Ye L, Cai H, Xia B, Yu X: PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Current Biology 2009, 19:524-529.

14. Reid S, Schindler D, Hansenberg H, Baker K, Hanks S, Kalb R, Neveling K, Kelli P, Seal S, Freund M, Wurm M, Batish SD, Lach FY, Yetgin S, Netzel H, Arriff H, Tischkowitz M, Mathew GG, Axetberg AD, Rahman N: Biliallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007, 39:162-164.

15. Rahman N: PALB2 and the BRCA2 partner PALB2. Nat Rev Cancer 2007, 7:R17-R39.

16. Zhang F, Ma J, Wu JX, Ye L, Cai H, Xia B, Yu X: PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Current Biology 2009, 19:524-529.

17. Basu SS, Wang D, Fajardo A, Hafeez M, Chen Y, Wang W, Livingston DM: PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 2009, 106:7155-7160.

18. Reynolds SA, Elston CW, Ellis IO, Pinder SE: Pathological prognostic factors in breast cancer. Crit Rev in Oncol Hematol 1999, 31:209-223.

19. Wolff AC, Hammond ME, Schwartz JN, Allred DC, Cote RJ, Dowsett M, Fritsch S, Goh KL, Hayes DF, Palma S, Poisson SI, Pritchard KI, Senn HJ, Hacker NF, Hayes DF, American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guidelines recommendation for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.

20. Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009, 4:1073-1082.

21. Ng PC, Henikoff S: SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003, 31:3812-3814.

22. Algin GVGD. [http://agvgd.iarc.fr].

23. Tavtigian SV, Deffenbaugh AM, Yen L, Judkins T, Schoff T, Samollow PB, de Silva D, Zakhari K, Thomas A: Comprehensive study of DNA misrepair has detected a number of DNA repair genes that are key to the development of breast cancer. J Natl Cancer Inst 2006, 98:921-931.

24. Metha E, Olivier M, Kato S, Ishioka C, Hainaut P, Tavtigian SV: Molecular Cell 2006, 22:719-729.

25. PolynPhen-2: prediction of functional effects of human nsSNPs. [http://polynph.umd.edu/pp2/2].
The spliceosome deposits early nonsense: mRNA decay solves a premature termination problem for mammalian embryonic viability. *Hum Mutat* 2011, 32:E2176-E2188.

54. Sy SMH, Huen MSY, Zhu Y, Chen JJ: PALB2 regulates recombination repair through chromatin association and oligomerization. *J Biol Chem* 2009, 284:18302-18310.

55. Sy SMH, Huen MSY, Chen JJ: MRG15 is a novel PALB2-interacting factor involved in homologous recombination. *J Biol Chem* 2009, 284:21127-21131.

56. Du et al.: Ech5, Fisch C, Saro D, Williams GJ, Hammel M, Yu X, Galkin VE, Liu D, Tsai MS, Sy SM, Schild D, Egelman E, Chen J, Sung P: Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. *Nat Struct Mol Biol* 2010, 17:1255-1259.

57. Hayakawa T, Zhang F, Hayakawa N, Ohtani Y, Shinnymouz K, Nakaaya J, Andreasen PR: MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks. *Cell* 2010, 123:1128-1130.

58. Jones S, Hurban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmasimo E, Brune K, Jaffe EM, Iacobuzio-Donahue CA, Mastra A, Parmigiani G, Kern SE, Velculescu VE, Kindred KV, Vogelstein B, Eshleman JR, Goggins M, Klein AP: Exonic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science* 2009, 324:217-217.

59. Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habibe N, Neoptolemos JP, Greenhalf W, Bartsch DJ: PALB2 mutations in European familial pancreatic cancer families. *Clin Genet* 2010, 78:490-494.

60. Tischkowitz MD, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, Srivistava A, Holter S, Rothenmund H, Ghadimian F, Foulkes WD, Gallinger S: Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. *Gastroenterology* 2009, 137:1183-1186.

61. Dansonka-Meszowski A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwińska A, Derlatka P, Cendrowski K, Kupynjacyck J: A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. *BMC Med Genet* 2010, 11:20.

62. Prokofyeva D, Bogdanova N, Berimbishova M, Zinnatullina G, Hilleman P, Khusnutdinova E: Dork T: Rare occurrence of PALB2 mutations in ovarian cancer patients from the Volga-Ural region. *Clin Genet* 2012, 82:100-101.

63. García MJ, Fernández V, Osorio A, Barroso A, Llort G, Lázaro C, Blanco I, Caldes T, de la Hoya M, Ramón Y Cajal T, Alonso C, Tejada MJ, San Román C, Robles-Díaz L, Urioste M, Benítez J: Analysis of FANCB and FANCL/PALB2 Fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. *Breast Cancer Res Treat* 2009, 113:545-551.

64. Tischkowitz M, Xia B: PALB2/FANCC: recombining cancer and Fanconi anemia. *Cancer Res* 2010, 70:7353-7359.

65. Heikininen T, Karkkinen H, Aaltonen K, Milne RL, Heikkilä P, Aittomäki K, Talseth-Palmer B, Bowden NA, Scott RJ: BRIP1, PALB2, and RAD51C germline mutations in familial and sporadic pancreatic cancer. *Hum Mutat* 2010, 31:1811-1816.

66. Castro MI, Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Costa M, Christiansen H, Rave-Frank M, Dork T, Imyanitov EN: Shao ZM: The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative breast and pancreatic cancer families. *Clin Genet* 2009, 76:421-426.

67. Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, Neoptolemos JP, Greenhalf W, Bartsch DJ: The contribution of founder mutations to early-onset breast cancer in French-Canadian women. *Cancer Genet* 2009, 198:1-9.

68. Altmann A, Kuppan S, Bieling I, Mbacké I, Querfeld U, Moch H, Grossmann O, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmasimo E, Brune K, Jaffe EM, Iacobuzio-Donahue CA, Mastra A, Parmigiani G, Kern SE, Velculescu VE, Kindred KV, Vogelstein B, Eshleman JR, Goggins M, Klein AP: Exonic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science* 2009, 324:217-217.

69. Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Hayakawa N, Ohtani Y, Shinmyozu K, Nakayama J, Hayakawa T: PALB2 1592delT is associated with an aggressive tumor phenotype. *Hum Mutat* 2009, 30:E2127-E2131.

70. Hayakawa T, Ohtani Y, Shinmyozu K, Nakayama J, Andreasen PR: MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks. *Cell* 2010, 123:1128-1130.

71. Jones S, Hurban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC, Palmasimo E, Brune K, Jaffe EM, Iacobuzio-Donahue CA, Mastra A, Parmigiani G, Kern SE, Velculescu VE, Kindred KV, Vogelstein B, Eshleman JR, Goggins M, Klein AP: Exonic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science* 2009, 324:217-217.

72. Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habibe N, Neoptolemos JP, Greenhalf W, Bartsch DJ: PALB2 mutations in European familial pancreatic cancer families. *Clin Genet* 2010, 78:490-494.

73. Tischkowitz MD, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, Srivistava A, Holter S, Rothenmund H, Ghadimian F, Foulkes WD, Gallinger S: Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. *Gastroenterology* 2009, 137:1183-1186.

74. Dansonka-Meszowski A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwińska A, Derlatka P, Cendrowski K, Kupynjacyck J: A novel germline PALB2 deletion in Polish breast and ovarian cancer patients. *BMC Med Genet* 2010, 11:20.

75. Prokofyeva D, Bogdanova N, Berimbishova M, Zinnatullina G, Hilleman P, Khusnutdinova E: Dork T: Rare occurrence of PALB2 mutations in ovarian cancer patients from the Volga-Ural region. *Clin Genet* 2012, 82:100-101.

76. García MJ, Fernández V, Osorio A, Barroso A, Llort G, Lázaro C, Blanco I, Caldes T, de la Hoya M, Ramón Y Cajal T, Alonso C, Tejada MJ, San Román C, Robles-Díaz L, Urioste M, Benítez J: Analysis of FANCB and FANCL/PALB2 Fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. *Breast Cancer Res Treat* 2009, 113:545-551.

77. Tischkowitz M, Xia B: PALB2/FANCC: recombining cancer and Fanconi anemia. *Cancer Res* 2010, 70:7353-7359.

78. Heikininen T, Karkkinen H, Aaltonen K, Milne RL, Heikkilä P, Atitomaki K, Barmat CR, Schmutzler RK, Deissler H, Ditsch N, Gress V, Kiechle M, Bartram CR, Schmutzler RK, Talseth-Palmer B, Bowden NA, Scott RJ: BRIP1, PALB2, and RAD51C germline mutations in familial and sporadic pancreatic cancer. *Hum Mutat* 2010, 31:1811-1816.

79. Castro MI, Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Costa M, Christiansen H, Rave-Frank M, Dork T, Imyanitov EN: Shao ZM: The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative breast and pancreatic cancer families. *Clin Genet* 2009, 76:421-426.
Author/s:
Teo, ZL; Park, DJ; Provenzano, E; Chatfield, CA; Odefrey, FA; Tu, N-D; Dowty, JG; Hopper, JL; Winship, I; Goldgar, DE; Southey, MC

Title:
Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families

Date:
2013-01-01

Citation:
Teo, Z. L., Park, D. J., Provenzano, E., Chatfield, C. A., Odefrey, F. A., Tu, N. -D., Dowty, J. G., Hopper, J. L., Winship, I., Goldgar, D. E. & Southey, M. C. (2013). Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families. BREAST CANCER RESEARCH, 15 (1), https://doi.org/10.1186/bcr3392.

Persistent Link:
http://hdl.handle.net/11343/265039

File Description:
Published version

License:
CC BY